These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32591491)

  • 21. Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization-a prospective, within-patient randomized study.
    van Roekel C; van den Hoven AF; Bastiaannet R; Bruijnen RCG; Braat AJAT; de Keizer B; Lam MGEH; Smits MLJ
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1658-1668. PubMed ID: 33128132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.
    Ebbers SC; van Roekel C; Braat MNGJA; Barentsz MW; Lam MGEH; Braat AJAT
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1700-1710. PubMed ID: 34873638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
    Liepe K; Brogsitter C; Leonhard J; Wunderlich G; Hliscs R; Pinkert J; Folprecht G; Kotzerke J
    Jpn J Clin Oncol; 2007 Dec; 37(12):942-50. PubMed ID: 18094017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial).
    Hendriks P; Rietbergen DDD; van Erkel AR; Coenraad MJ; Arntz MJ; Bennink RJ; Braat AE; Crobach S; van Delden OM; Dibbets-Schneider P; van der Hulle T; Klümpen HJ; van der Meer RW; Nijsen JFW; van Rijswijk CSP; Roosen J; Ruijter BN; Smit F; Stam MK; Takkenberg RB; Tushuizen ME; van Velden FHP; de Geus-Oei LF; Burgmans MC;
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2085-2097. PubMed ID: 38329507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Safety and Feasibility of Same-Day Holmium-166 -Radioembolization Simulation and Treatment of Hepatic Metastases.
    van Roekel C; Harlianto NI; Braat AJAT; Prince JF; van den Hoven AF; Bruijnen RCG; Lam MGEH; Smits MLJ
    J Vasc Interv Radiol; 2020 Oct; 31(10):1593-1599. PubMed ID: 32861571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
    Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
    J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
    Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
    J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioembolization with
    Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatotoxic Dose Thresholds by Positron-Emission Tomography After Yttrium-90 Radioembolization of Liver Tumors: A Prospective Single-Arm Observational Study.
    Chan KT; Alessio AM; Johnson GE; Vaidya S; Kwan SW; Monsky W; Wilson AE; Lewis DH; Padia SA
    Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1363-1372. PubMed ID: 29651580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of
    Reinders MTM; van Erpecum KJ; Smits MLJ; Braat AJAT; Bruijne J; Bruijnen R; Sprengers D; Man RA; Vegt E; IJzermans JNM; Moelker A; Lam MGEH
    J Nucl Med; 2022 Dec; 63(12):1891-1898. PubMed ID: 35589409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating therapeutic efficacy of extended shelf-life 90 Y glass microspheres in transarterial radioembolization for colorectal cancer: a quantitative FDG PET/CT analysis.
    Kesim S; Balaban Genc ZC; Soydemir E; Baltacioglu F; Kissa TN; Ozdemir B; Ozguven S; Filizoglu N; Niftaliyeva K; Engur CO; Kostek O; Akdeniz E; Turoglu HT; Erdil TY; Cimsit C; Ones T
    Nucl Med Commun; 2024 Apr; 45(4):268-277. PubMed ID: 38214074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
    Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
    Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
    Garin E; Rolland Y; Edeline J; Icard N; Lenoir L; Laffont S; Mesbah H; Breton M; Sulpice L; Boudjema K; Rohou T; Raoul JL; Clement B; Boucher E
    J Nucl Med; 2015 Mar; 56(3):339-46. PubMed ID: 25678490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study.
    Braat AJAT; Prince JF; van Rooij R; Bruijnen RCG; van den Bosch MAAJ; Lam MGEH
    Eur Radiol; 2018 Mar; 28(3):920-928. PubMed ID: 28786008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study.
    Topcuoglu OM; Orhan T; Gormez A; Alan N
    Br J Radiol; 2024 Jun; 97(1159):1255-1260. PubMed ID: 38730551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.
    Levillain H; Duran Derijckere I; Ameye L; Guiot T; Braat A; Meyer C; Vanderlinden B; Reynaert N; Hendlisz A; Lam M; Deroose CM; Ahmadzadehfar H; Flamen P
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2270-2279. PubMed ID: 31324943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance imaging-based radiation-absorbed dose estimation of 166Ho microspheres in liver radioembolization.
    Seevinck PR; van de Maat GH; de Wit TC; Vente MA; Nijsen JF; Bakker CJ
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e437-44. PubMed ID: 22633554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.